Research programme: checkpoint kinase inhibitors - Pfizer
Latest Information Update: 22 Sep 2006
At a glance
- Originator Agouron Pharmaceuticals; Pfizer
- Developer Agouron Pharmaceuticals
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 19 Oct 2004 This programme is still in active development - 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004)
- 19 Oct 2004 Preclinical trials in Cancer in USA (unspecified route)